About: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

clinical trial

Attributes	Values
rdf:type	Item
description	clinical trial (en) ensayo clínico (es) ensayu clínicu (ast) klinisch onderzoek (nl) клінічне випробування (uk) կլինիկական փորձարկում (hy)
rdfs:label	Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (en) Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (nl)
skos:prefLabel	Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (en) Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (nl)
name	Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (en) Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (nl)
title	wds:Q105788846-85E10FDD-EF76-4DA9-B32F-D0306132B1DD
title	A Phase II Multi-Arm Study to Test the Efficacy of Oleclumab and Durvalumab in Multiple Sarcoma Subtypes (en)
end time	wds:Q105788846-1741517E-2F30-4617-A835-5060CCDCE5D0
end time	2024-06-30 00:00:00Z (xsd:dateTime)
instance of	wds:Q105788846-A37921DF-4646-4977-AF6F-5455AAE2DE82
instance of	clinical trial
start time	wds:Q105788846-00303C87-1B02-40E4-A43A-51781B29CCEA
start time	2020-12-03 00:00:00Z (xsd:dateTime)
country	wds:Q105788846-923D3025-00FA-4C02-8D8A-57EB254E264A
country	United States of America
short name	wds:Q105788846-E7B521B9-7B70-446C-A442-1F085473D72F
short name	DOSa (en)
research intervention	wds:Q105788846-1254B454-FB69-4200-81DE-450AA5CFD9DE wds:Q105788846-406E67E8-F205-445E-8F55-8169C359A783 wds:Q105788846-F129FCC4-8B4A-48F0-AE18-681ECFD69E09
research intervention	durvalumab immunoglobulin intravenous immunoglobulin
minimum age	wds:Q105788846-CBD408BE-AD5F-42B2-BBC2-59DF82745113
minimum age	12 (xsd:decimal)
medical condition	wds:Q105788846-0721E484-52E9-45CC-A532-04C02CAA46E4 wds:Q105788846-2561ABCA-8A34-4BE9-8666-2852B67A9C6F wds:Q105788846-E739E1F0-0DEE-44EA-9C73-B3C7356CA95E
sponsor	wds:Q105788846-BD078C85-008C-401E-8BD6-9C981F1F858F
medical condition	sarcoma osteosarcoma liposarcoma
sponsor	The University of Texas MD Anderson Cancer Center
number of participants	wds:Q105788846-17CD3BF3-C5A3-4B43-8032-453A8E2DAC44
number of participants	75 (xsd:decimal)
contributor to the...e work or subject	wds:Q105788846-7379556F-81C1-4F70-89EC-A956DFD20A53
contributor to the...e work or subject	National Cancer Institute
study type	wds:Q105788846-74AD9224-DBAC-43DB-911F-E81D40256C78
study type	interventional study
ClinicalTrials.gov ID	wds:Q105788846-BA88112D-2614-4B1F-9595-D5A9A63B2AE0
ClinicalTrials.gov ID	NCT04668300
clinical trial phase	wds:Q105788846-6CA3D74E-A19E-49CF-A962-8AEDF5C27237
clinical trial phase	phase II clinical trial
research subject recruitment status	wds:Q105788846-B73EFA31-A9C3-49ED-AF96-B3B57C6F504F
research subject recruitment status	recruiting
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q105788846

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software